Cargando…
Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons
BACKGROUND: Uptake of Isoniazid Preventive Therapy (IPT) among People Living with HIV in Zambia has continued to be low despite various evidence for its added benefit in reducing TB incidence and mortality when taken with antiretroviral therapy. In 2017, only 18% of People Living with HIV newly enro...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805296/ https://www.ncbi.nlm.nih.gov/pubmed/31640657 http://dx.doi.org/10.1186/s12889-019-7652-x |
_version_ | 1783461348992090112 |
---|---|
author | Kagujje, Mary Mubiana, Muhau L. Mwamba, Eugenia Muyoyeta, Monde |
author_facet | Kagujje, Mary Mubiana, Muhau L. Mwamba, Eugenia Muyoyeta, Monde |
author_sort | Kagujje, Mary |
collection | PubMed |
description | BACKGROUND: Uptake of Isoniazid Preventive Therapy (IPT) among People Living with HIV in Zambia has continued to be low despite various evidence for its added benefit in reducing TB incidence and mortality when taken with antiretroviral therapy. In 2017, only 18% of People Living with HIV newly enrolled in care were initiated on IPT in Zambia. MAIN TEXT: Various challenges including policy and management level factors, supply chain factors, health worker perceptions about IPT, monitoring and evaluation factors and limited demand creation activities have constrained the scale up of IPT in Zambia. Lessons that have been learnt while addressing the above challenges are shared and they can be applied by government ministries, project managers, public health specialists to strengthen IPT activities in their settings. CONCLUSION: Zambia has both a high burden of TB and HIV and without preventing new cases of TB from reactivation of latent TB infection, it will be difficult to control TB. All stakeholders involved in prevention of TB among PLHIV need to commit to addressing the challenges limiting scale up of IPT. |
format | Online Article Text |
id | pubmed-6805296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68052962019-10-24 Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons Kagujje, Mary Mubiana, Muhau L. Mwamba, Eugenia Muyoyeta, Monde BMC Public Health Debate BACKGROUND: Uptake of Isoniazid Preventive Therapy (IPT) among People Living with HIV in Zambia has continued to be low despite various evidence for its added benefit in reducing TB incidence and mortality when taken with antiretroviral therapy. In 2017, only 18% of People Living with HIV newly enrolled in care were initiated on IPT in Zambia. MAIN TEXT: Various challenges including policy and management level factors, supply chain factors, health worker perceptions about IPT, monitoring and evaluation factors and limited demand creation activities have constrained the scale up of IPT in Zambia. Lessons that have been learnt while addressing the above challenges are shared and they can be applied by government ministries, project managers, public health specialists to strengthen IPT activities in their settings. CONCLUSION: Zambia has both a high burden of TB and HIV and without preventing new cases of TB from reactivation of latent TB infection, it will be difficult to control TB. All stakeholders involved in prevention of TB among PLHIV need to commit to addressing the challenges limiting scale up of IPT. BioMed Central 2019-10-22 /pmc/articles/PMC6805296/ /pubmed/31640657 http://dx.doi.org/10.1186/s12889-019-7652-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Debate Kagujje, Mary Mubiana, Muhau L. Mwamba, Eugenia Muyoyeta, Monde Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons |
title | Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons |
title_full | Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons |
title_fullStr | Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons |
title_full_unstemmed | Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons |
title_short | Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons |
title_sort | implementation of isoniazid preventive therapy in people living with hiv in zambia: challenges and lessons |
topic | Debate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805296/ https://www.ncbi.nlm.nih.gov/pubmed/31640657 http://dx.doi.org/10.1186/s12889-019-7652-x |
work_keys_str_mv | AT kagujjemary implementationofisoniazidpreventivetherapyinpeoplelivingwithhivinzambiachallengesandlessons AT mubianamuhaul implementationofisoniazidpreventivetherapyinpeoplelivingwithhivinzambiachallengesandlessons AT mwambaeugenia implementationofisoniazidpreventivetherapyinpeoplelivingwithhivinzambiachallengesandlessons AT muyoyetamonde implementationofisoniazidpreventivetherapyinpeoplelivingwithhivinzambiachallengesandlessons |